Blood therapy products maker Baxter International Inc said it would buy the blood disorder-related assets of privately held biopharmaceutical firm Archemix for a $30 million upfront payment.
122787
Baxter buys blood disorder assets from Archemix
167804
Dentsu to buy Aegis for £3.2bn
118225
Oxygen Healthcare signs agreement with Phytopharm
9174
Mylan acquires generic injectables unit from Strides Arcolab
41320
LabCorp strikes deal for Alzheimer's disease diagnostic
175195
EQT Partners buys Springer Science and Business Media
128654
MDRNA buys DNA technology from Valeant Pharmaceuticals for undisclosed amount
31894
Merck to buy Schering-Plough for $41 billion
154583
Nasdaq OMX Group completes acquisition of Boston Stock Exchange
86964
Evonik acquires catalyst business from HC Starck
80180
Novartis buys rights to new antibiotic
166968
Affymetrix to acquire Panomics
43090
Boston Scientific to acquire BridgePoint Medical
101184
HealthStream acquires Sy.Med
64947
Pharmasset publicly offers $92.8 million in stock
12617
Alchemia to spin off oncology business
112080
Solutia initiates stock offering